These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38000211)
21. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats. Kaumann AJ; Galindo-Tovar A; Escudero E; Vargas ML Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):421-30. PubMed ID: 19693491 [TBL] [Abstract][Full Text] [Related]
22. An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential. Zheng L; Zhou ZZ Eur J Med Chem; 2023 Nov; 259():115682. PubMed ID: 37536210 [TBL] [Abstract][Full Text] [Related]
23. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium. Shimizu K; Murata T; Tagawa T; Takahashi K; Ishikawa R; Abe Y; Hosaka K; Kubohara Y Cancer Res; 2004 Apr; 64(7):2568-71. PubMed ID: 15059913 [TBL] [Abstract][Full Text] [Related]
24. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Murray F; Patel HH; Suda RY; Zhang S; Thistlethwaite PA; Yuan JX; Insel PA Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L294-303. PubMed ID: 16980375 [TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase inhibitors in airways disease. Fan Chung K Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289 [TBL] [Abstract][Full Text] [Related]
26. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6. White JB; Thompson WJ; Pittler SJ Mol Vis; 2004 Oct; 10():738-49. PubMed ID: 15480303 [TBL] [Abstract][Full Text] [Related]
27. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation. Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295 [TBL] [Abstract][Full Text] [Related]
28. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523 [TBL] [Abstract][Full Text] [Related]
29. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis. Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454 [TBL] [Abstract][Full Text] [Related]
30. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex. Sutor B; Mantell K; Bacher B Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358 [TBL] [Abstract][Full Text] [Related]
31. Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins. Nichols MR; Morimoto BH Mol Pharmacol; 2000 Apr; 57(4):738-45. PubMed ID: 10727520 [TBL] [Abstract][Full Text] [Related]
32. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. Vandeput F; Krall J; Ockaili R; Salloum FN; Florio V; Corbin JD; Francis SH; Kukreja RC; Movsesian MA J Pharmacol Exp Ther; 2009 Sep; 330(3):884-91. PubMed ID: 19546307 [TBL] [Abstract][Full Text] [Related]
34. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity. Tulsian NK; Sin VJ; Koh HL; Anand GS Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491 [TBL] [Abstract][Full Text] [Related]
35. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Phillips PG; Long L; Wilkins MR; Morrell NW Am J Physiol Lung Cell Mol Physiol; 2005 Jan; 288(1):L103-15. PubMed ID: 15377497 [TBL] [Abstract][Full Text] [Related]
36. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum. Qiu Y; Kraft P; Lombardi E; Clancy J J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172 [TBL] [Abstract][Full Text] [Related]
38. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Castro A; Jerez MJ; Gil C; Martinez A Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991 [TBL] [Abstract][Full Text] [Related]
39. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. Suvarna NU; O'Donnell JM J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724 [TBL] [Abstract][Full Text] [Related]
40. Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10). Deng C; Wang D; Bugaj-Gaweda B; De Vivo M Curr Protoc Neurosci; 2007 Jan; Chapter 7():Unit 7.21. PubMed ID: 18428663 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]